Navigation Links
PPCE Announces Strategic Partnership With ECLINSO AG
Date:9/13/2012

PUNE, India, Sept. 13, 2012 /PRNewswire-iReach/ -- PPCE, a high-quality Clinical Data Management services company providing CDISC-certified services announced today that it has entered into a strategic partnership agreement with ECLINSO AG, a leading provider of eClinical information technology, consulting and business process outsourcing services.

PPCE Data Management Services and ECLINSO's Trialforce Platform offer unparalleled flexibility and adaptability to both Sponsors and Clinical Research Organizations (CROs) for capturing and managing their clinical data.

With extensive experience in serving pharmaceutical and biotechnology companies of all sizes, PPCE, a company based in Pune, India has selected ECLINSO's Trialforce platform to enable it to offer high-quality eClinical application services and optimized data management services to their clients.

Trialforce a single, unified application platform is a comprehensive, on demand, SaaS based solution for conducting Clinical Trials. It offers enterprise class software for Electronic Data Capture (EDC), Electronic Source Record (ESR), eTMF aligned Document Management (DMS), Diagnostic imaging, and Regulatory Solutions (eCTD).

ECLINSO's strong foundation of managed IT services, dedicated on demand servers and global 24/7 support, offers Sponsors and Clinical Research Organizations CDISC compliant solutions designed to accelerate clinical development.

"PPCE is delighted to have reached this partnership agreement with ECLINSO, enabling us to offer enterprise class eClinical solutions and services.

ECLINSO's Trialforce platform accelerates the whole clinical trial process and thus saves time and money which will enable PPCE to efficiently continue providing its clients with the high-quality eClinical solutions and services they have come to expect. Our combined experience and resources will significantly improve clinical trial efficiency while reducing costs for our clients," stated Firdaus Dastoor, Chairman PPCE.

"PPCE's strong presence with global organizations and proven established execution capability throughout Asia will enable ECLINSO to fulfill increasing customer demand for its Trialforce platform," said Frank Pijpers, CEO ECLINSO.

About ECLINSO (www.eclinso.com)

ECLINSO is an innovative provider of Clinical Technology solutions and global support services to enhance the conduct of clinical trials. Our international reputation combined with our deep industry understanding and innovative approach through Trialforce is setting the benchmark for the use of 'on demand' solutions for clinical trials. Through Trialforce we deliver an innovative standards, affordable, scalable and easy-to-use platform that enables sponsors and CRO's to rapidly deploy an integrated EDC/Data Management/eClinical suite. The solution is based on an uncomplicated SaaS pricing model, that offers minimal upfront costs and significantly lower initial licensing fees compared to those fees traditionally associated with the use of EDC solutions.

ECLINSO was formed in 1995 and has offices in Basel, Switzerland, New Jersey and California, USA.

About PPCE (www.ppceworld.com)

Established in 1997, PPCE offers cost effective clinical data management and bio-statistical services for paper based, electronic and hybrid studies.  Solutions used are validated, world renowned and regulatory compliant across the globe.  Fully validated, 21 CFR Part 11 compliant platforms like Oracle Clinical and Trialforce enable PPCE to offer its clients world class tools for high quality data.

We are a company focused on quality and on-time delivery for our clients.  PPCE's sixteen years of experience certifying companies for quality management means that critical aspects of quality, such as integrity of data, confidentiality and customer orientation, form part of the organizational culture.  As a result of this culture we enjoy a high level of customer satisfaction and long term relationships with our clients.

Contact:
Jaya Kumawat
Head-Biometrics, PPCE
+ 91 20 2674 5024

Media Contact: George Masoura ECLINSO, 855 245 0987, george.masoura@eclinso.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE ECLINSO
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
2. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
3. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
4. Henry Schein Announces New $500 Million Credit Facility
5. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
6. Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
7. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
8. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
9. Elbit Imaging Ltd. Announces Standard & Poors Maalot Changes Rating of Companys Notes
10. 3SBio Inc. Announces Receipt of "Going Private" Proposal at $15 Per ADS
11. IncellDx, Inc. Announces an Agreement with BioReference Laboratories, Inc. to Conduct a 10,000 Sample Study Using a Slideless Pap Smear
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 23, 2017  The particle counters market ... 2021 from USD 275.9 million in 2016, at ... full report: http://www.reportlinker.com/p04718602-summary/view-report.html The ... pharmaceutical R&D, and growth in manufacturing industries in ... growth for particle counters. On the other hand, ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
(Date:2/23/2017)... Nevro Corp. (NYSE: NVRO), a global medical device company that ... pain, today reported financial results for the three months and ... Accomplishment & Highlights: Achieved revenue of $228.5 ... as reported, over the prior year U.S. revenue ... the prior year International revenue of $55.2 ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 23, 2017 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Miami Beach to host its Swirl: Miami Wine Tasting Event on March 28, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., ... From Not to Hot,” which will begin airing on February 24, 2017. The show ... from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series ...
(Date:2/23/2017)... Mass. (PRWEB) , ... February 23, 2017 , ... ... as an approved content provider for the National Institute for Health and ... and social care-related organizations in the National Health Service (NHS) to search, order ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... exciting, new, interactive publication where generations converge and explore the world from different ... worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and find greater ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... and community for those in the fight against cancer, has produced a seminal ... success. HRA will release top-line findings in a webinar, Defining Compassionate Care ...
Breaking Medicine News(10 mins):